ASH 2023: MRD Highlights in BioPharma Drug Development

Read More

Browse our 650+ Publications​

Latest Publications

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

Hall MS, et al.
Journal for ImmunoTherapy of Cancer
November 2023
Authors and Affiliates
MacLean S Hall 1,2, Jamie K Teer 3, Xiaoqing Yu 3, Holly Branthoover 1, Sebastian Snedal 1, Madeline Rodriguez-Valentin 1, Luz Nagle 1, Ellen Scott 1, Ben Schachner 1, Patrick Innamarato 1, Amy M Hall 1, Jamie Blauvelt 1, Carolyn J Rich 4, Allison D Richards 4, Jake Ceccarelli 5, T J Langer 5, Sean J Yoder 6, Matthew S Beatty 1, Cheryl A Cox 7, Jane L Messina 8, Daniel Abate-Daga 1, James J Mule 1, John E Mullinax 1,9, Amod A Sarnaik 1,4, Shari Pilon-Thomas 10; 1 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 2 Cancer Biology PhD Program, University of South Florida, Tampa, Florida, USA. 3 Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 4 Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 5 Turnstone Biologics, Inc, San Diego, California, USA. 6 Molecular Genomics Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 7 Cell Therapies Core Facility, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 8 Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 9 Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA. 10 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA shari.pilon-thomas@moffitt.org.

Recruitment of naïve CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity

Laing KJ, et al.
Journal of Clinical Investigation
November 2023
Authors and Affiliates
Kerry J Laing 1, Emily S Ford 1, Michael J Johnson 2, Myron J Levin 3, David M Koelle 1, Adriana Weinberg 2; 1 Department of Medicine, University of Washington, Seattle, United States of America. 2 Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, United States of America. 3 Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, United States of America.

Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma

Secrier M, et al.
Cancer Research Communication
November 2023
Authors and Affiliates
Maria Secrier 1,2, Lara McGrath 3, Felicia Ng 4, Sakshi Gulati 1, Amelia Raymond 3, Barrett R B Nuttall 3, Julie Berthe 1, Emma V Jones 1, Ben S Sidders 4, Jérôme Galon 5,6,7, J Carl Barrett 3, Helen K Angell 1; 1 Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. 2 UCL Genetics Institute, Department of Genetics, Evolution and Environment, University College London, London, United Kingdom. 3 Translational Medicine, Oncology R&D, AstraZeneca, Boston, Massachusetts. 4 Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. 5 INSERM, Laboratory of Integrative Cancer Immunology, Paris, France. 6 Sorbonne Université, Université Paris Cité, Centre de Recherche des Cordeliers, Paris, France. 7 Equipe Labellisée Ligue Contre le Cancer, Paris, France.

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

Niemann C, et al.
Lancet Oncology
November 2023
Authors and Affiliates
Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianya Qi, Pierre Sinet, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P Kater

Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.

Izutsu K, et al.
Cancer Science
November 2023
Authors and Affiliates
Koji Izutsu, Takahiro Kumode, Junichiro Yuda, Hirokazu Nagai, Yuko Mishima, Youko Suehiro, Kazuhito Yamamoto, Tomoaki Fujisaki, Kenji Ishitsuka, Kenichi Ishizawa, Takayuki Ikezoe, Momoko Nishikori, Daigo Akahane, Jiro Fujita, Minh Dinh, David Soong, Hidehisa Noguchi, Jeppe Klint Buchbjerg, Elena Favaro, Noriko Fukuhara

CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.

Minson A, et al.
Blood
October 2023
Authors and Affiliates
Adrian G Minson, Nada Hamad, Chan Y Cheah, Constantine S Tam, Piers Blombery, David A Westerman, David S Ritchie, Huw Morgan, Nicholas Holzwart, Stephen Lade, Mary Ann Anderson, Amit Khot, John F Seymour, Molly Robertson, Imogen Caldwell, Georgina Ryland, Javad Saghebi, Zahra Sabahi, Jing Xie, Rachel M Koldej, Michael Dickinson Citation

Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes from a Single-Center Study

Ashouri K, et al.
Clinical Lymphoma Myeloma & Leukemia
October 2023
Authors and Affiliates
Karam Ashouri, Vinay Nittur, Anush A. Ginosyan, Jennifer Hwang, Blake Adnani, Denaly Chen, Lakshmi Sav itala-Damerla, Kimberly Schiff, Preet Chaudhary, Alexandra E. Kovach, Abdullah Ladha, Imran Siddiqi, Amir Ali, Karrune Woan, Eric Tam, George Yaghmour

Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma

Naghavian R, et al.
Nature
October 2023
Authors and Affiliates
Reza Naghavian 1,2, Wolfgang Faigle 1,2,3, Pietro Oldrati 1, Jian Wang 1,4, Nora C Toussaint 5,6, Yuhan Qiu 1, Gioele Medici 7, Marcel Wacker 8,9,10,11, Lena K Freudenmann 9,10,11, Pierre-Emmanuel Bonté 3, Michael Weller 12, Luca Regli 7, Sebastian Amigorena 3, Hans-Georg Rammensee 9,10,11, Juliane S Walz 8,9,10,11,13, Silvio D Brugger 14, Malte Mohme 15, Yingdong Zhao 16, Mireia Sospedra 1,2, Marian C Neidert 7,17, Roland Martin 18,19,20,21; 1 Neuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, Zurich, Switzerland. 2 Cellerys AG, Schlieren, Switzerland. 3 Immunity and Cancer, Institut Curie, PSL University, INSERM U932, Paris, France. 4 School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. 5 NEXUS Personalized Health Technologies, ETH Zurich, Schlieren, Switzerland. 6 Swiss Institute of Bioinformatics, Zurich, Switzerland. 7 Clinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 8 Department of Peptide-based Immunotherapy, University of Tübingen, University Hospital Tübingen, Tübingen, Germany. 9 Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. 10 German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Tübingen, Germany. 11 Cluster of Excellence iFIT (EXC 2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany. 12 Laboratory of Molecular Neuro-Oncology, Department of Neurology and Clinical Neuroscience, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 13 Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany. 14 Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 15 Department of Neurosurgery, University Hospital Hamburg Eppendorf, University of Hamburg, Hamburg, Germany. 16 Computational and Systems Biology Branch, Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA. 17 Department of Neurosurgery, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. 18 Neuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, Zurich, Switzerland. roland.martin@uzh.ch. 19 Cellerys AG, Schlieren, Switzerland. roland.martin@uzh.ch. 20 Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. roland.martin@uzh.ch. 21 Therapeutic Immune Design Unit, Center for Molecular Medicine, Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden. roland.martin@uzh.ch.

Analysis of CDR3 Sequences from T-Cell Receptor β in Acute Respiratory Distress Syndrome

Hey S, et al.
Biomolecules
October 2023
Authors and Affiliates
Sara Hey 1, Dayjah Whyte 1, Minh-Chau Hoang 1, Nick Le 1, Joseph Natvig 1, Claire Wingfield 1, Charles Onyeama 2, Judie Howrylak 3, Inimary T Toby 1; 1 Department of Biology, University of Dallas, Irving, TX 75062, USA. 2 T.C Pediatrics, Bedford, TX 76021, USA. 3 Pulmonary, Allergy and Critical Care Division, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA.

Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy

Desai AP, et al.
Journal for ImmunoTherapy of Cancer
October 2023
Authors and Affiliates
Aakash P Desai 1, Farhad Kosari 2, Maria Disselhorst 3, Jun Yin 4, Alireza Agahi 5, Tobias Peikert 6, Julia Udell 5, Sarah H Johnson 5, James Smadbeck 5, Stephen Murphy 7, Giannoula Karagouga 5, Alexa McCune 5, Janet Schaefer-Klein 5, Mitesh J Borad 8, John Cheville 7, George Vasmatzis 2, Paul Baas 3, Aaron Mansfield 9; 1 Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA. 2 Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA. 3 Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 4 Quantitative Health Sciences, Mayo Clinic Rochester, Rochester, Minnesota, USA. 5 Center for Individualized Medicine, Mayo Clinic Rochester, Rochester, Minnesota, USA. 6 Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA. 7 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 8 Hematology/Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA. 9 Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA Mansfield.Aaron@mayo.edu.